# Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

> **NCT00408499** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 64 (actual)

## Conditions studied

- Lung Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** cetuximab
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00408499
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-04
- **Final completion:** 2013-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408499, "Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00408499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*